RecruitingNot ApplicableNCT06850285

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified T Cells Targeting CD30 in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

Sponsor

Shanxi Bethune Hospital

Enrollment

15 participants

Start Date

Sep 5, 2025

Study Type

INTERVENTIONAL

Conditions

Lymphoma, B-Cell

Summary

The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。

Eligibility

Min Age: 15 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing CD30-targeted CAR T-cell therapy — a treatment where a patient's own immune cells are engineered to seek out and destroy cancer cells bearing the CD30 protein — for patients with lymphoma (a blood cancer) that has come back or stopped responding to standard treatments. **You may be eligible if...** - You are between 15 and 80 years old - You have a lymphoma that tests positive for the CD30 protein (more than 10% of cells express CD30) - You have at least one measurable area of disease visible on imaging - Your lymphoma has relapsed after or is not responding to standard therapy - You are not a candidate for, or have already had, an autologous stem cell transplant **You may NOT be eligible if...** - Your lymphoma does not express CD30 - You have significant heart, liver, or kidney problems - You have an active serious infection or autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGchimeric antigen receptor gene modified T cells

The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.